» Articles » PMID: 38506114

Stress in the Metastatic Journey - the Role of Cell Communication and Clustering in Breast Cancer Progression and Treatment Resistance

Overview
Journal Dis Model Mech
Specialty General Medicine
Date 2024 Mar 20
PMID 38506114
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer stands as the most prevalent malignancy afflicting women. Despite significant advancements in its diagnosis and treatment, breast cancer metastasis continues to be a leading cause of mortality among women. To metastasize, cancer cells face numerous challenges: breaking away from the primary tumor, surviving in the circulation, establishing in a distant location, evading immune detection and, finally, thriving to initiate a new tumor. Each of these sequential steps requires cancer cells to adapt to a myriad of stressors and develop survival mechanisms. In addition, most patients with breast cancer undergo surgical removal of their primary tumor and have various therapeutic interventions designed to eradicate cancer cells. Despite this plethora of attacks and stresses, certain cancer cells not only manage to persist but also proliferate robustly, giving rise to substantial tumors that frequently culminate in the patient's demise. To enhance patient outcomes, there is an imperative need for a deeper understanding of the molecular and cellular mechanisms that empower cancer cells to not only survive but also expand. Herein, we delve into the intrinsic stresses that cancer cells encounter throughout the metastatic journey and the additional stresses induced by therapeutic interventions. We focus on elucidating the remarkable strategies adopted by cancer cells, such as cell-cell clustering and intricate cell-cell communication mechanisms, to ensure their survival.

Citing Articles

GJA1-20k, a Short Isoform of Connexin43, from Its Discovery to Its Potential Implication in Cancer Progression.

Fournier S, Clarhaut J, Cronier L, Monvoisin A Cells. 2025; 14(3).

PMID: 39936974 PMC: 11817742. DOI: 10.3390/cells14030180.


Targeting PGK1: A New Frontier in Breast Cancer Therapy Under Hypoxic Conditions.

Cui J, Chai S, Liu R, Shen G Curr Issues Mol Biol. 2024; 46(11):12214-12229.

PMID: 39590319 PMC: 11593045. DOI: 10.3390/cimb46110725.


Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma.

Rahman M, Ali M Cancers (Basel). 2024; 16(17).

PMID: 39272834 PMC: 11394361. DOI: 10.3390/cancers16172975.


Breast Cancer: Extracellular Matrix and Microbiome Interactions.

Herrera-Quintana L, Vazquez-Lorente H, Plaza-Diaz J Int J Mol Sci. 2024; 25(13).

PMID: 39000333 PMC: 11242809. DOI: 10.3390/ijms25137226.

References
1.
Ichim G, Lopez J, Ahmed S, Muthalagu N, Giampazolias E, Delgado M . Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol Cell. 2015; 57(5):860-872. PMC: 4352766. DOI: 10.1016/j.molcel.2015.01.018. View

2.
Larsson A, Jansson S, Bendahl P, Jorgensen C, Loman N, Graffman C . Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res. 2018; 20(1):48. PMC: 5994056. DOI: 10.1186/s13058-018-0976-0. View

3.
Egan K, Cooke N, Kenny D . Living in shear: platelets protect cancer cells from shear induced damage. Clin Exp Metastasis. 2014; 31(6):697-704. DOI: 10.1007/s10585-014-9660-7. View

4.
Gao H, Chakraborty G, Lee-Lim A, Mo Q, Decker M, Vonica A . The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 2012; 150(4):764-79. PMC: 3711709. DOI: 10.1016/j.cell.2012.06.035. View

5.
Paoli P, Giannoni E, Chiarugi P . Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013; 1833(12):3481-3498. DOI: 10.1016/j.bbamcr.2013.06.026. View